— Why it moved
Why PEPG Stock Spiked and Faded Today — November 10, 2026
PepGen put out good Phase 2 trial data before the session's start, but instantly paired it with a $125 million share dilution that crushed the move by afternoon.
What moved PEPG stock
PepGen Inc. is a clinical-stage biotech firm developing therapies for neuromuscular diseases. They dropped positive Phase 2 data for their myotonic dystrophy drug showing solid splicing correction. Management immediately used the spike to dump a proposed $125 million stock offering on the market.
The mechanics
The stock gapped up 123% on 106 million shares of volume against a 36 million share float. High-volume biotech news spikes like this get systematically capped the minute secondary offerings enter the picture.
PEPG by the numbers
The alert window
We alerted PEPG at $5.73 at 9:19 AM. You had to endure a drop to $5.15 down 10% before it clawed back up to $6.49 at 9:49 AM. That gave a modest 13.2% window over 30 minutes, but holding past mid-morning was a mistake.
How PEPG's move ended
PepGen closed at $4.61, down 19.6% from the alert price. The clinical data was good, but a $125 million equity offering against a $165 million market cap guarantees heavy dilution.
The tell: When a micro-cap biotech drops good clinical trial data, check for an equity offering before trading the gap.